|
DOXRIBTIMINE
 INN DOXRIBTIMINE
|
cas 50-89-5 |
CLASS METABOLISM PYRIMIDINE NUCLEOSIDE TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) INCORPORATED INTO SKELETAL MUSCLE MITOCHONDRIAL DEOXYRIBONUCLEIC ACID (DNA) |
|
ATC code
A16AX29 |
PK parameters Tmax 4 HOUR PPB 10 PERCENT t1/2 5 HOUR
|
Target TARGET DNA |
DrugCentral - |
Download SDF file |
Thymidine Formula: C10H14N2O5 Calculated chemical properties: MW 242.23 NB_atoms 17 XLogP -1.51 PSA 100.68 NB_HD 3 NB_HA 7 fsp3 0.60 Lipinski(0=no;1=yes) 1 |
FDA NDA 219792 ( label) INN (DOXECITINE ; DOXRIBTIMINE) KYGEVVI (UCB INC) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY |
Other links: PubChem ChemicalProbes U.S. repository of Clinical Trials VigiAccess SIDER side effects ChemSynthesis Patent@SureChEMBL |